{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:30:31Z","timestamp":1789673431914,"version":"4.0.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s00520-019-05001-x","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T10:59:40Z","timestamp":1563965980000},"page":"1849-1854","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Risk factors for febrile neutropenia in neoadjuvant docetaxel, cisplatin, and 5-fluorouracil chemotherapy for esophageal cancer"],"prefix":"10.1007","volume":"28","author":[{"given":"Hisanaga","family":"Nomura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Hatogai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Maki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Daiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikatsu","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,24]]},"reference":[{"key":"5001_CR1","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1470-2045(07)70039-6","volume":"8","author":"V Gebski","year":"2007","unstructured":"Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8:226\u2013234","journal-title":"Lancet Oncol"},{"key":"5001_CR2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S1470-2045(11)70142-5","volume":"12","author":"KM Sjoquist","year":"2011","unstructured":"Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12:681\u2013692","journal-title":"Lancet Oncol"},{"key":"5001_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1245\/s10434-011-2049-9","volume":"19","author":"N Ando","year":"2012","unstructured":"Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, Ikeda K, Kanda T, Tsujinaka T, Nakamura K, Fukuda H (2012) A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19:68\u201374","journal-title":"Ann Surg Oncol"},{"key":"5001_CR4","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/cas.12274","volume":"104","author":"H Hara","year":"2013","unstructured":"Hara H, Tahara M, Daiko H, Kato K, Igaki H, Kadowaki S, Tanaka Y, Hamamoto Y, Matsushita H, Nagase M, Hosoya Y (2013) Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci 104:1455\u20131460","journal-title":"Cancer Sci"},{"key":"5001_CR5","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1093\/jjco\/hyt061","volume":"43","author":"K Nakamura","year":"2013","unstructured":"Nakamura K, Kato K, Igaki H, Ito Y, Mizusawa J, Ando N, Udagawa H, Tsubosa Y, Daiko H, Hironaka S, Fukuda H, Kitagawa Y, on behalf of the Japan Esophageal Oncology Group\/Japan Clinical Oncology Group (2013) Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol 43:752\u2013755","journal-title":"Jpn J Clin Oncol"},{"key":"5001_CR6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","volume":"90","author":"GH Lyman","year":"2014","unstructured":"Lyman GH, Abella E, Pettengell R (2014) Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol 90:190\u2013199","journal-title":"Crit Rev Oncol Hematol"},{"key":"5001_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00464-017-5688-5","volume":"32","author":"Y Akiyama","year":"2018","unstructured":"Akiyama Y, Iwaya T, Endo F, Chiba T, Takahara T, Otsuka K, Nitta H, Koeda K, Mizuno M, Kimura Y, Sasaki A (2018) Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma. Surg Endosc 32:391\u2013399","journal-title":"Surg Endosc"},{"key":"5001_CR8","first-page":"3053","volume":"37","author":"H Miyata","year":"2017","unstructured":"Miyata H, Sugimura K, Motoori M et al (2017) Clinical assessment of sarcopenia and changes in body composition during neoadjuvant chemotherapy for esophageal cancer. Anticancer Res 37:3053\u20133059","journal-title":"Anticancer Res"},{"key":"5001_CR9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000455128","volume":"92","author":"K Yamashita","year":"2017","unstructured":"Yamashita K, Hosoda K, Moriya H, Katada C, Sugawara M, Mieno H, Komori S, Katada N, Watanabe M (2017) Prognostic advantage of docetaxel\/cisplatin\/ 5-fluorouracil neoadjuvant chemotherapy in clinical stage II\/III esophageal squamous cell carcinoma due to excellent control of preoperative disease and postoperative lymph node recurrence. Oncology 92:221\u2013228","journal-title":"Oncology"},{"key":"5001_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00280-016-3062-2","volume":"78","author":"H Satake","year":"2016","unstructured":"Satake H, Tahara M, Mochizuki S, Kato K, Hara H, Yokota T, Kiyota N, Kii T, Chin K, Zenda S, Kojima T, Bando H, Yamazaki T, Iwasa S, Honma Y, Hamauchi S, Tsushima T, Ohtsu A (2016) A prospective, multicenter phase I\/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma. Cancer Chemother Pharmacol 78:91\u201399","journal-title":"Cancer Chemother Pharmacol"},{"key":"5001_CR11","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","volume":"375","author":"RE Sherman","year":"2016","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, LaVange L, Marinac-Dabic D, Marks PW, Robb MA, Shuren J, Temple R, Woodcock J, Yue LQ, Califf RM (2016) Real-world evidence - what is it and what can it tell us? N Engl J Med 375:2293\u20132297","journal-title":"N Engl J Med"},{"key":"5001_CR12","doi-asserted-by":"publisher","first-page":"5336","DOI":"10.1002\/cncr.25537","volume":"116","author":"LH Sobin","year":"2010","unstructured":"Sobin LH, Compton CC (2010) TNM seventh edition: what\u2019s new, what\u2019s changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer 116:5336\u20135339","journal-title":"Cancer"},{"key":"5001_CR13","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJMoa044097","volume":"353","author":"G Bucaneve","year":"2005","unstructured":"Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D\u2019Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Fo\u00e0 R, del Favero A (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353:977\u2013987","journal-title":"N Engl J Med"},{"key":"5001_CR14","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 52:e56\u2013e93","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"5001_CR15","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1086\/383054","volume":"39","author":"T Masaoka","year":"2004","unstructured":"Masaoka T (2004) Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis 39(Suppl 1):S49\u2013S52","journal-title":"Clin Infect Dis"},{"key":"5001_CR16","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1200\/JCO.1998.16.3.1179","volume":"16","author":"EA Engels","year":"1998","unstructured":"Engels EA, Lau J, Barza M (1998) Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 16:1179\u20131187","journal-title":"J Clin Oncol"},{"key":"5001_CR17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/dote.12187","volume":"28","author":"T Ui","year":"2015","unstructured":"Ui T, Fujii H, Hosoya Y, Nagase M, Mieno MN, Mori M, Zuiki T, Saito S, Kurashina K, Haruta H, Matsumoto S, Niki T, Lefor A, Yasuda Y (2015) Comparison of preoperative chemotherapy using docetaxel, cisplatin and fluorouracil with cisplatin and fluorouracil in patients with advanced carcinoma of the thoracic esophagus. Dis Esophagus 28:180\u2013187","journal-title":"Dis Esophagus"},{"key":"5001_CR18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.ygyno.2012.03.015","volume":"125","author":"RA Laskey","year":"2012","unstructured":"Laskey RA, Poniewierski MS, Lopez MA, Hanna RK, Secord AA, Gehrig PA, Lyman GH, Havrilesky LJ (2012) Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer. Gynecol Oncol 125:625\u2013630","journal-title":"Gynecol Oncol"},{"key":"5001_CR19","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1200\/JCO.2017.77.6211","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston K, Strasfeld L, Flowers CR (2018) Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. J Clin Oncol 36:1443\u20131453","journal-title":"J Clin Oncol"},{"key":"5001_CR20","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J (2016) ESMO Guidelines Committee. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol 27:v111\u2013v118","journal-title":"Ann Oncol"},{"key":"5001_CR21","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1200\/jco.2011.29.4_suppl.95","volume":"29","author":"K Kato","year":"2011","unstructured":"Kato K, Hara H, Daiko H et al (2011) Feasibility study of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil (DCF) for clinical stage II\/III esophageal squamous cell carcinoma. J Clin Oncol 29:S95\u2013S95","journal-title":"J Clin Oncol"},{"key":"5001_CR22","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1002\/cncr.11827","volume":"98","author":"GH Lyman","year":"2003","unstructured":"Lyman GH, Delgado DJ (2003) Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 98:2402\u20132409","journal-title":"Cancer"},{"key":"5001_CR23","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/j.1532-5415.2010.02837.x","volume":"58","author":"M Kuzuya","year":"2010","unstructured":"Kuzuya M, Enoki H, Izawa S, Hasegawa J, Suzuki Y, Iguchi A (2010) Factors associated with nonadherence to medication in community-dwelling disabled older adults in Japan. J Am Geriatr Soc 58:1007\u20131009","journal-title":"J Am Geriatr Soc"},{"key":"5001_CR24","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/cncr.21422","volume":"104","author":"A Hurria","year":"2005","unstructured":"Hurria A, Gupta S, Zauderer M, Zuckerman EL, Cohen HJ, Muss H, Rodin M, Panageas KS, Holland JC, Saltz L, Kris MG, Noy A, Gomez J, Jakubowski A, Hudis C, Kornblith AB (2005) Developing a cancer-specific geriatric assessment: a feasibility study. Cancer 104:1998\u20132005","journal-title":"Cancer"},{"key":"5001_CR25","first-page":"1011","volume":"34","author":"H Kobayashi","year":"1986","unstructured":"Kobayashi H, Takamura K, Takeda H et al (1986) Comparative clinical study of ciprofloxacin and cefaclor in the treatment of respiratory tract infections. Chemotherapy 34:1011\u20131037","journal-title":"Chemotherapy"},{"key":"5001_CR26","first-page":"629","volume":"34","author":"K Hara","year":"1986","unstructured":"Hara K, Saito A, Yamaguchi K et al (1986) Comparative study of BAYo9867 (ciprofloxacin) and bacampicillin on bacterial pneumonia by double blind method. Chemotherapy 34:629\u2013653","journal-title":"Chemotherapy"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-05001-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-019-05001-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-05001-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T23:19:43Z","timestamp":1595459983000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-019-05001-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,24]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["5001"],"URL":"https:\/\/doi.org\/10.1007\/s00520-019-05001-x","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,24]]},"assertion":[{"value":"23 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with 1964 Helsinki Declaration and its later amendment or comparable ethical standards. For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}